Infection-control measures reduce transmission of vancomycin-resistant enterococci in an endemic setting

Ann Intern Med. 1999 Aug 17;131(4):269-72. doi: 10.7326/0003-4819-131-4-199908170-00006.

Abstract

Background: Vancomycin-resistant enterococci (VRE) are nosocomial pathogens in many U. S. hospitals.

Objective: To determine whether enhanced infection-control strategies reduce transmission of VRE in an endemic setting.

Design: Prospective cohort study.

Setting: Adult oncology inpatient unit.

Patients: 259 patients evaluated during use of enhanced infection-control strategies and 184 patients evaluated during use of standard infection-control practices.

Interventions: Patient surveillance cultures were taken, patients were assigned to geographic cohorts, nurses were assigned to patient cohorts, gowns and gloves were worn on room entry, compliance with infection-control procedures was monitored, patients were educated about VRE transmission, patients taking antimicrobial agents were evaluated by an infectious disease specialist, and environmental surveillance was performed.

Measurements: VRE infection rates, VRE colonization rates, and changes in antimicrobial use.

Results: During use of enhanced infection-control strategies, incidence of VRE bloodstream infections decreased significantly (0.45 patients per 1000 patient-days compared with 2.1 patients per 1000 patient-days; relative rate ratio, 0.22 [95% CI, 0.05 to 0.92]; P = 0.04), as did VRE colonization (10.3 patients per 1000 patient-days compared with 20.7 patients per 1000 patient-days; relative rate ratio, 0.5 [CI, 0.33 to 0.75]; P < 0.001). Use of all antimicrobial agents except clindamycin and amikacin was significantly reduced.

Conclusion: Enhanced infection-control strategies reduced VRE transmission in an oncology unit in which VRE were endemic.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology*
  • Cross Infection / prevention & control*
  • Drug Resistance, Microbial
  • Enterococcus / drug effects*
  • Gram-Positive Bacterial Infections / prevention & control*
  • Humans
  • Infection Control*
  • Oncology Service, Hospital
  • Prospective Studies
  • Vancomycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Vancomycin